Trial Profile
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dalteparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions
- Acronyms ADAM VTE trial
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results obtaining the outcomes from CARAVAGGIO, HOKUSAI-VTE, ADAM VTE and SELECT-D and analysing Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2020 Status changed from active, no longer recruiting to completed.